---
layout: default
title: Ferrous Gluconate
description: "Ferrous Gluconate çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 5 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 73
evidence_level: L5
indication_count: 5
---

# Ferrous Gluconate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>5</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ferrous Gluconate (è‘¡è„ç³–é…¸äºéµ) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ferrous Gluconate å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
è‘¡è„ç³–é…¸äºéµæ˜¯ä¸€ç¨®å‚³çµ±è£œéµåŠ‘ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å° Plummer-Vinson ç—‡å€™ç¾¤ç­‰ç½•è¦‹è²§è¡€ç›¸é—œç–¾ç—…æœ‰ç™‚æ•ˆï¼Œé€™äº›é æ¸¬èˆ‡å…¶å·²çŸ¥çš„éµè£œå……æ©Ÿåˆ¶é«˜åº¦ä¸€è‡´ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©å­¸å | Ferrous Gluconate |
| å°ç£å•†å“å | è‘¡è„ç³–é…¸éµç³–è¡£éŒ ã€ç¶­ä»–è‘¡è„ç³–éµç³–è¡£éŒ ã€è¡€å‘½å¥ç³–è¡£ç‰‡ç­‰ |
| DrugBank ID | DB14488 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | éµç¼ºä¹æ€§è²§è¡€ã€å¦Šå¨ è²§è¡€ã€ç‡Ÿé¤Šä¸è‰¯ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | Plummer-Vinson ç—‡å€™ç¾¤ã€ç¶­ç”Ÿç´ ç¼ºä¹ç—‡ã€å·¨ç´…è¡€çƒæ€§è²§è¡€ |
| æœ€é«˜è­‰æ“šç­‰ç´š | L3 (è§€å¯Ÿæ€§ç ”ç©¶) |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | æœ‰æ•ˆè¨±å¯è­‰ |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. Plummer-Vinson syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

è‘¡è„ç³–é…¸äºéµä½œç‚ºéµè£œå……åŠ‘ï¼Œå…¶é æ¸¬é©æ‡‰ç—‡èˆ‡åŸæ ¸å‡†é©æ‡‰ç—‡å…·æœ‰é«˜åº¦çš„æ©Ÿè½‰ç›¸ä¼¼æ€§ï¼š

1. **Plummer-Vinson ç—‡å€™ç¾¤** (TxGNN Score: 0.999, Rank: 1843)ï¼šæ­¤ç—‡å€™ç¾¤çš„å…¸å‹ä¸‰è¯ç—‡ç‚ºç¼ºéµæ€§è²§è¡€ã€ååš¥å›°é›£å’Œé£Ÿé“ç¶²ç‹€è†œï¼ŒéµåŠ‘è£œå……æ˜¯æ¨™æº–æ²»ç™‚æ–¹å¼ï¼Œé æ¸¬éå¸¸åˆç†ã€‚

2. **ç¶­ç”Ÿç´  B12 å’Œè‘‰é…¸ç¨ç«‹æ€§å…ˆå¤©æ€§å·¨ç´…è¡€çƒæ€§è²§è¡€** (TxGNN Score: 0.999, Rank: 1894)ï¼šé›–ç„¶åç¨±æç¤ºèˆ‡ B12/è‘‰é…¸ç„¡é—œï¼Œä½†éµç¼ºä¹å¯èƒ½æ˜¯æ­¤é¡è²§è¡€çš„å…±ç—…å› ç´ ã€‚

3. **ç¶­ç”Ÿç´ ç¼ºä¹ç—‡** (TxGNN Score: 0.992, Rank: 14603)ï¼šéµåŠ‘å¸¸èˆ‡ç¶­ç”Ÿç´ è¤‡åˆè£½åŠ‘ä½µç”¨ï¼Œä¸”éµç¼ºä¹å¸¸èˆ‡å…¶ä»–ç‡Ÿé¤Šç´ ç¼ºä¹åŒæ™‚å‡ºç¾ã€‚

### è‡¨åºŠè©¦é©—

é‡å°ã€Œç¶­ç”Ÿç´ ç¼ºä¹ç—‡ã€é©æ‡‰ç—‡ï¼Œæª¢ç´¢åˆ° 4 é …ç›¸é—œè‡¨åºŠè©¦é©—ï¼š

| è©¦é©—ç·¨è™Ÿ | æ¨™é¡Œ | éšæ®µ | ç‹€æ…‹ | åœ‹å®¶ |
|----------|------|------|------|------|
| NCT07366502 | ä½åŠ‘é‡è„‚è³ªé«”éµ vs å‚³çµ±å£æœéµæ²»ç™‚èƒƒè¢–æ‰‹è¡“å¾Œç¼ºéµæ€§è²§è¡€ | NA | æ‹›å‹Ÿä¸­ | åœŸè€³å…¶ |
| NCT06869824 | å¯Œéµç‡Ÿé¤Šè»Ÿç³–å°å¥³æ€§è²§è¡€çš„ç™‚æ•ˆè©•ä¼° | NA | å·²å®Œæˆ | ä¸­åœ‹ |
| NCT02233322 | éµæ²»ç™‚è‡ªé«”é¡¯æ€§ä½ç£·é…¸é¹½è¡€ç—‡æ€§ä½åƒ‚ç—… | NA | å·²å®Œæˆ | ç¾åœ‹ |
| NCT06642337 | ç‡Ÿé¤Šæ•™è‚²è¨ˆç•«å°å…’ç«¥ç¼ºéµæ€§è²§è¡€çš„å½±éŸ¿ | NA | é€²è¡Œä¸­ | ä¼Šæ‹‰å…‹ |

**è­‰æ“šç­‰ç´šï¼šL3** - æœ‰è§€å¯Ÿæ€§ç ”ç©¶å’Œéƒ¨åˆ† RCT æ•¸æ“šæ”¯æŒéµåŠ‘åœ¨å„é¡è²§è¡€åŠç‡Ÿé¤Šç¼ºä¹ç—‡çš„ç™‚æ•ˆã€‚

### ç›¸é—œæ–‡ç»

æª¢ç´¢åˆ° 2 ç¯‡ç›¸é—œ PubMed æ–‡ç»ï¼š

1. **Kalus U et al. (2008)** - Transfusion Medicine
   - æ¢è¨æè¡€å°æ°´æº¶æ€§ç¶­ç”Ÿç´ å«é‡çš„å½±éŸ¿
   - ç™¼ç¾éµèˆ‡ç¶­ç”Ÿç´ ç‹€æ…‹é–“å­˜åœ¨é—œè¯æ€§

2. **Huber J (1988)** - Wiener Medizinische Wochenschrift
   - RCT ç ”ç©¶éµ-è‘‰é…¸è¤‡åˆè£½åŠ‘åœ¨å¦Šå¨ æœŸçš„ä½¿ç”¨
   - é¡¯ç¤ºè‰¯å¥½çš„è¡€æ¶²å­¸æ”¹å–„åŠè…¸èƒƒè€å—æ€§

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. vitamin B12- and folate-independent constitutional megaloblastic anemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. non-syndromic esophageal malformation</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.67%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.67%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. biotin metabolic disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.42%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. vitamin deficiency disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.17%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.17%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

**æœ‰æ•ˆè¨±å¯è­‰ï¼ˆéƒ¨åˆ†ï¼‰ï¼š**
- å…§è¡›è—¥è£½å­—ç¬¬002605è™Ÿ - è‘¡è„ç³–é…¸éµç³–è¡£éŒ ï¼ˆå¤©ä¸‹ç”Ÿç‰©ç§‘æŠ€ï¼‰- æœ‰æ•ˆè‡³ 2029/05/25
- å…§è¡›è—¥è£½å­—ç¬¬001822è™Ÿ - ç¶­ä»–è‘¡è„ç³–éµç³–è¡£éŒ ï¼ˆå¼·ç”ŸåŒ–å­¸ï¼‰- æœ‰æ•ˆè‡³ 2029/05/25
- å…§è¡›è—¥è£½å­—ç¬¬009171è™Ÿ - è¡€å‘½å¥ç³–è¡£ç‰‡ï¼ˆä¿¡æ±ç”ŸæŠ€ï¼‰- æœ‰æ•ˆè‡³ 2028/05/25
- è¡›éƒ¨è—¥è¼¸å­—ç¬¬028799è™Ÿ - è‘¡è„ç³–é…¸äºéµï¼ˆèª å“è²¿æ˜“ï¼‰- æœ‰æ•ˆè‡³ 2029/09/05

**ç¸½è¨ˆï¼š** 22 ç­†ç›¸é—œè¨±å¯è­‰ç´€éŒ„ï¼Œå…¶ä¸­å¤šç­†ç‚ºæœ‰æ•ˆè¨±å¯è­‰ã€‚

## å®‰å…¨æ€§è€ƒé‡

### ä¸»è¦è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| Dimercaprol | Major | è¯åˆåŠ‘å¯èƒ½æ¸›å°‘éµå¸æ”¶ |
| Dolutegravir | Major | æŠ—åè½‰éŒ„ç—…æ¯’è—¥ç‰©å¸æ”¶å¯èƒ½å—å½±éŸ¿ |
| Bictegravir | Major | åŒä¸Š |
| è³ªå­å¹«æµ¦æŠ‘åˆ¶åŠ‘ (PPIs) | Moderate | æ¸›å°‘èƒƒé…¸åˆ†æ³Œï¼Œé™ä½éµå¸æ”¶ |
| å››ç’°ç´ é¡æŠ—ç”Ÿç´  | Moderate | å½¢æˆè¯åˆç‰©ï¼Œé›™å‘é™ä½å¸æ”¶ |
| Quinolone é¡æŠ—ç”Ÿç´  | Moderate | å½¢æˆè¯åˆç‰©ï¼Œé™ä½æŠ—ç”Ÿç´ å¸æ”¶ |
| Levothyroxine | Moderate | å¯èƒ½é™ä½ç”²ç‹€è…ºç´ å¸æ”¶ |
| åˆ¶é…¸åŠ‘ | Moderate | é™ä½éµå¸æ”¶ |

**å…±è¨˜éŒ„ 80 é …è—¥ç‰©äº¤äº’ä½œç”¨ã€‚**

### ä¸€èˆ¬æ³¨æ„äº‹é …
- å»ºè­°ç©ºè…¹æœç”¨ä»¥å¢åŠ å¸æ”¶
- èˆ‡ç¶­ç”Ÿç´  C ä½µæœå¯å¢åŠ å¸æ”¶
- å¯èƒ½å¼•èµ·è…¸èƒƒä¸é©ã€ä¾¿ç§˜æˆ–é»‘ä¾¿
- éé‡å¯èƒ½å°è‡´éµä¸­æ¯’

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é£Ÿç‰© (food)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šConcomitant use of some food may reduce the bioavailability of orally administered iron, and vice versa.
- å»ºè­°ï¼šIdeally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closel...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Achlorhydria** ğŸŸ¡ Moderate
- Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary...

**Gastrointestinal Diseases** ğŸŸ¡ Moderate
- Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.

**Hemoglobinopathies** ğŸŸ¢ Minor
- There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficienc...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°çµè«–

è‘¡è„ç³–é…¸äºéµçš„é æ¸¬é©æ‡‰ç—‡ï¼ˆPlummer-Vinson ç—‡å€™ç¾¤ã€ç¶­ç”Ÿç´ ç¼ºä¹ç›¸é—œè²§è¡€ï¼‰èˆ‡å…¶ä½œç‚ºéµè£œå……åŠ‘çš„è—¥ç†æ©Ÿè½‰é«˜åº¦ä¸€è‡´ã€‚Plummer-Vinson ç—‡å€™ç¾¤çš„é æ¸¬å°¤å…¶å…·æœ‰è‡¨åºŠæ„ç¾©ï¼Œå› ç‚ºéµè£œå……ç¢ºå¯¦æ˜¯è©²ç—‡å€™ç¾¤çš„æ¨™æº–æ²»ç™‚ã€‚

### è­‰æ“šç­‰ç´šç¸½çµ

| é æ¸¬é©æ‡‰ç—‡ | TxGNN Score | è­‰æ“šç­‰ç´š | è©•ä¼° |
|------------|-------------|----------|------|
| Plummer-Vinson ç—‡å€™ç¾¤ | 0.999 | L5 | æ©Ÿè½‰åˆç†ï¼Œè‡¨åºŠå·²ç¢ºç«‹ |
| å·¨ç´…è¡€çƒæ€§è²§è¡€ | 0.999 | L5 | å¯èƒ½ç‚ºå…±ç—…æ²»ç™‚ |
| ç¶­ç”Ÿç´ ç¼ºä¹ç—‡ | 0.992 | L3 | æœ‰è‡¨åºŠè©¦é©—æ”¯æŒ |

### å»ºè­°

1. **Plummer-Vinson ç—‡å€™ç¾¤**ï¼šæ­¤é æ¸¬å¯¦éš›ä¸Šåæ˜ äº†æ—¢æœ‰çš„è‡¨åºŠå¯¦å‹™ï¼Œç„¡éœ€é¡å¤–ç ”ç©¶å³å¯ç¢ºèª
2. **ç¶­ç”Ÿç´ ç¼ºä¹ç—‡**ï¼šä½œç‚ºè¤‡åˆç‡Ÿé¤Šè£œå……çš„ä¸€éƒ¨åˆ†ï¼Œè‡¨åºŠåƒ¹å€¼å·²ç¢ºç«‹
3. **å…¶ä»–é æ¸¬é©æ‡‰ç—‡**ï¼šéœ€æ›´å¤šè­‰æ“šæ”¯æŒ

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN çŸ¥è­˜åœ–è­œé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Flunitrazepam]({{ "/drugs/flunitrazepam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cladribine]({{ "/drugs/cladribine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ipilimumab]({{ "/drugs/ipilimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trihexyphenidyl]({{ "/drugs/trihexyphenidyl/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sodium Carbonate]({{ "/drugs/sodium_carbonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ferrous Gluconateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ferrous_gluconate/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ferrous_gluconate,
  title = {Ferrous Gluconateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ferrous_gluconate/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
